Cisplatin-induced pyroptosis is mediated via the CAPN1/CAPN2-BAK/BAX-caspase-9-caspase-3-GSDME axis in esophageal cancer

Li, Rong-Yao; Zheng, Zhen-Yuan; Li, Zhi-Mao; Heng, Jing-Hua; Zheng, Ya-Qi; Deng, Dan-Xia; Xu, Xiu‐E; Liao, Lian‐Di; Lin, Wan-Wan; Xu, Hanbing; Huang, Huaiyi; Li, En‐Min; Xu, Li‐Yan

doi:10.1016/j.cbi.2022.109967

Cited by 26 publications

(13 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin can activate pyroptosis through the MEG3 / NLRP3 / caspase-1 / GSDMD pathway to exert anti-tumor effects in triple-negative breast cancer 21 . Similarly, cisplatin can also mediate pyroptosis in esophageal cancer cells and lung cancer cells 23, 30 . In this study, the enrichment analysis of differential genes before and after cisplatin treatment showed that the differential genes were mainly concentrated in neurodegenerative diseases, amyotrophic lateral sclerosis, Alzheimer ’s disease, Parkinson ’s disease, human papillomavirus infection and shigellosis.…”

Section: Discussionmentioning

confidence: 99%

“…Clinical use of cisplatin in ovarian cancer, prostate cancer, testicular cancer, lung cancer, nasopharyngeal carcinoma, esophageal cancer, malignant lymphoma, head and neck squamous cell carcinoma, thyroid cancer and osteosarcoma and other solid tumors can show efficacy 19,20 . Recent studies have shown that cisplatin can activate pyroptosis to mediate gastric cancer cells after acting on cancer cells, which has a new direction for the mechanism of cisplatin as a chemotherapeutic drug to kill gastric cancer cells [21][22][23] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cisplatin promotes pyroptosis of gastric cancer cells by activating GSDME

Jiang,

Wang,

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

According to studies, numerous chemotherapeutic drugs can facilitate programmed cell death via pyroptosis. Clarifying the mechanism by which cisplatin kills gastric cancer cells is crucial for enhancing gastric cancer’s sensitivity to chemotherapy and elucidating the mechanism of drug resistance in gastric cancer. The differentially expressed genes following cisplatin treatment were identified using second-generation sequencing technology. Bioinformatics was used to investigate the functional enrichment of differentially expressed genes and core genes in tumor cells killed by cisplatin. Cox regression analyses were used to examine the pyroptosis core genes that worked as independent prognostic factors for patients with gastric cancer. The expression of core genes in gastric cancer cells was silenced by siRNA, and the changes in the proliferation of gastric cancer cells were observed. The expression of related genes and the survival of gastric cancer cells after the addition of cisplatin were observed. The second-generation sequencing, RT-PCR and Western blotting showed that the pyroptosis core gene was significantly highly expressed after cisplatin treatment. The results of differential gene enrichment of cisplatin-treated gastric cancer cells showed that differential genes were mainly concentrated in biological processes and signaling pathways related to pyroptosis. GSDME protein is highly expressed after cisplatin treatment, and it is also a poor prognostic factor for gastric cancer patients and an independent prognostic factor. After the same dose of cisplatin treatment, the survival rate of siGSDME gastric cancer cells was significantly higher than that of GSDME regular expression gastric cancer cells. After acting on gastric cancer cells, cisplatin triggers pyroptosis by stimulating the activation of genes such as GSDME, resulting in the death of gastric cancer cells. GSDME is an independent prognostic factor for gastric cancer patients and is significantly linked with a shorter OS. In gastric cancer cells, silencing GSDME can substantially reduce cisplatin’s cytotoxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cisplatin promotes pyroptosis of gastric cancer cells by activating GSDME

Jiang,

Wang,

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In addition, Yu et al have shown a relationship between NLRP3 and esophageal squamous cell carcinoma (ESCC) progression; an enhanced expression of NLRP3 in ESCC is associated with higher pathological stages 50 . In addition, cisplatin induces pyroptosis via activation of the CAPN1/CAPN2‐BAK/BAX‐caspase‐9‐caspase‐3‐GSDME pathway in esophageal cancer cells 51 . This provides a possibility to guide the treatment of esophageal cancer.…”

Section: Pyroptosis In Digestive Tract Tumorsmentioning

confidence: 99%

“…50 In addition, cisplatin induces pyroptosis via activation of the CAPN1/CAPN2-BAK/BAX-caspase-9-caspase-3-GSDME pathway in esophageal cancer cells. 51 This provides a possibility to guide the treatment of esophageal cancer.…”

Section: Pyroptosis In Digestive Tract Tumorsmentioning

confidence: 99%

Recent updates on pyroptosis in tumors of the digestive tract

Wang,

Shang,

et al. 2023

J of Digest Diseases

View full text Add to dashboard Cite

Pyroptosis is an inflammasome‐dependent form of programmed cell death that is mediated by caspase‐1,caspase‐4/5/11 and the gasdermin protein family. It is characterized by the rupture of cell membranes, the release of cell contents and interleukins, the associated inflammatory reaction and immune system activation. Recent studies have suggested that pyroptosis plays a role in the development of digestive tract tumors，both impeding tumor generation and progression, as well as providing a favorable microenvironment for tumor growth. This review outlines the current knowledge regarding the implications of pyroptosis in gastrointestinal cancers with a focus on providing insights into their pathogenesis and potential treatments.This article is protected by copyright. All rights reserved.

show abstract

“…At present, the research on pyroptosis and EC mainly focuses on promoting the sensitivity of EC cells to chemoradiotherapy through inducing pyroptosis of EC cells via various drugs or techniques ( Wu et al, 2019 ; Fang et al, 2020 ; Li et al, 2021b ; Li et al, 2022b ), but there are still few studies on pyroptosis and ESCC, the roles and mechanisms of pyroptosis in ESCC are far from clear ( Jiang et al, 2021 ), and more studies are needed to elucidate the relationship between ESCC and the pyroptosis phenotype.…”

Section: Introductionmentioning

confidence: 99%

A novel pyroptosis scoring model was associated with the prognosis and immune microenvironment of esophageal squamous cell carcinoma

Zhang

2023

Front. Genet.

View full text Add to dashboard Cite

The phenotype of pyroptosis has been extensively studied in a variety of tumors, but the relationship between pyroptosis and esophageal squamous cell carcinoma (ESCC) remains unclear. Here, 22 pyroptosis genes were downloaded from the website of Gene Set Enrichment Analysis (GSEA), 79 esophageal squamous cell carcinoma samples and GSE53625 containing 179 pairs of esophageal squamous cell carcinoma samples were collected from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), respectively. Then, pyroptosis subtypes of esophageal squamous cell carcinoma were obtained by cluster analysis according to the expression difference of pyroptosis genes, and a pyroptosis scoring model was constructed by the pyroptosis-related genes screened from different pyroptosis subtypes. Time-dependent receiver operator characteristic (timeROC) curves and the area under the curve (AUC) values were used to evaluate the prognostic predictive accuracy of the pyroptosis scoring model. Kaplan-Meier method with log-rank test were conducted to analyze the impact of the pyroptosis scoring model on overall survival (OS) of patients with esophageal squamous cell carcinoma. Nomogram models and calibration curves were used to further confirm the effect of the pyroptosis scoring model on prognosis. Meanwhile, CIBERSORTx and ESTIMATE algorithm were applied to calculate the influence of the pyroptosis scoring model on esophageal squamous cell carcinoma immune microenvironment. Our findings revealed that the pyroptosis scoring model established by the pyroptosis-related genes was associated with the prognosis and immune microenvironment of esophageal squamous cell carcinoma, which can be used as a biomarker to predict the prognosis and act as a potential target for the treatment of esophageal squamous cell carcinoma.

show abstract

Cisplatin-induced pyroptosis is mediated via the CAPN1/CAPN2-BAK/BAX-caspase-9-caspase-3-GSDME axis in esophageal cancer

Cited by 26 publications

References 67 publications

Cisplatin promotes pyroptosis of gastric cancer cells by activating GSDME

Cisplatin promotes pyroptosis of gastric cancer cells by activating GSDME

Recent updates on pyroptosis in tumors of the digestive tract

A novel pyroptosis scoring model was associated with the prognosis and immune microenvironment of esophageal squamous cell carcinoma

Contact Info

Product

Resources

About